Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)
about
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)
description
2020 nî lūn-bûn
@nan
2020年の論文
@ja
2020年学术文章
@wuu
2020年学术文章
@zh
2020年学术文章
@zh-cn
2020年学术文章
@zh-hans
2020年学术文章
@zh-my
2020年学术文章
@zh-sg
2020年學術文章
@yue
2020年學術文章
@zh-hant
name
Phase II evaluation of copanli ...... NRG Oncology study (NRG-GY008)
@en
type
label
Phase II evaluation of copanli ...... NRG Oncology study (NRG-GY008)
@en
prefLabel
Phase II evaluation of copanli ...... NRG Oncology study (NRG-GY008)
@en
P2093
P1476
Phase II evaluation of copanli ...... NRG Oncology study (NRG-GY008)
@en
P2093
Alessandro D Santin
Barbara M Buttin
Camille C Gunderson
Cara A Mathews
Elena S Ratner
Guilherme Cantuaria
Heather A Lankes
Michael Frumovitz
Michael J Birrer
Samir N Khleif
P304
P356
10.1016/J.GORE.2019.100532
P577
2020-01-02T00:00:00Z